These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30460626)

  • 1. Quantification of [
    Serrano ME; Bahri MA; Becker G; Seret A; Mievis F; Giacomelli F; Lemaire C; Salmon E; Luxen A; Plenevaux A
    Mol Imaging Biol; 2019 Oct; 21(5):888-897. PubMed ID: 30460626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain.
    Nabulsi NB; Mercier J; Holden D; Carré S; Najafzadeh S; Vandergeten MC; Lin SF; Deo A; Price N; Wood M; Lara-Jaime T; Montel F; Laruelle M; Carson RE; Hannestad J; Huang Y
    J Nucl Med; 2016 May; 57(5):777-84. PubMed ID: 26848175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of 18F-UCB-H as a novel PET tracer for synaptic vesicle protein 2A in the brain.
    Warnock GI; Aerts J; Bahri MA; Bretin F; Lemaire C; Giacomelli F; Mievis F; Mestdagh N; Buchanan T; Valade A; Mercier J; Wood M; Gillard M; Seret A; Luxen A; Salmon E; Plenevaux A
    J Nucl Med; 2014 Aug; 55(8):1336-41. PubMed ID: 24935992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the In Vivo Specificity of [
    Serrano ME; Becker G; Bahri MA; Seret A; Mestdagh N; Mercier J; Mievis F; Giacomelli F; Lemaire C; Salmon E; Luxen A; Plenevaux A
    Molecules; 2019 May; 24(9):. PubMed ID: 31052478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo imaging of synaptic density with [
    Xiong M; Roshanbin S; Rokka J; Schlein E; Ingelsson M; Sehlin D; Eriksson J; Syvänen S
    Neuroimage; 2021 Oct; 239():118302. PubMed ID: 34174391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring with [
    Serrano ME; Bahri MA; Becker G; Seret A; Germonpré C; Lemaire C; Giacomelli F; Mievis F; Luxen A; Salmon E; Rogister B; Raedt R; Plenevaux A
    Mol Imaging Biol; 2020 Oct; 22(5):1197-1207. PubMed ID: 32206990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation and noninvasive kinetic modeling of [
    Bertoglio D; Verhaeghe J; Miranda A; Kertesz I; Cybulska K; Korat Š; Wyffels L; Stroobants S; Mrzljak L; Dominguez C; Liu L; Skinbjerg M; Munoz-Sanjuan I; Staelens S
    J Cereb Blood Flow Metab; 2020 Jun; 40(6):1351-1362. PubMed ID: 31307287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-in-Human Evaluation of
    Naganawa M; Li S; Nabulsi N; Henry S; Zheng MQ; Pracitto R; Cai Z; Gao H; Kapinos M; Labaree D; Matuskey D; Huang Y; Carson RE
    J Nucl Med; 2021 Apr; 62(4):561-567. PubMed ID: 32859701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of synaptic loss in mouse models of β-amyloid and tau pathology using [
    Vogler L; Ballweg A; Bohr B; Briel N; Wind K; Antons M; Kunze LH; Gnörich J; Lindner S; Gildehaus FJ; Baumann K; Bartenstein P; Boening G; Ziegler SI; Levin J; Zwergal A; Höglinger GU; Herms J; Brendel M
    Neuroimage Clin; 2023; 39():103484. PubMed ID: 37541098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers.
    Constantinescu CC; Tresse C; Zheng M; Gouasmat A; Carroll VM; Mistico L; Alagille D; Sandiego CM; Papin C; Marek K; Seibyl JP; Tamagnan GD; Barret O
    Mol Imaging Biol; 2019 Jun; 21(3):509-518. PubMed ID: 30084043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantifying SV2A density and drug occupancy in the human brain using [
    Koole M; van Aalst J; Devrome M; Mertens N; Serdons K; Lacroix B; Mercier J; Sciberras D; Maguire P; Van Laere K
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):396-406. PubMed ID: 30121895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and in vivo evaluation of [
    Li S; Cai Z; Zhang W; Holden D; Lin SF; Finnema SJ; Shirali A; Ropchan J; Carre S; Mercier J; Carson RE; Nabulsi N; Huang Y
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1952-1965. PubMed ID: 31175396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodistribution and Radiation Dosimetry for the Novel SV2A Radiotracer [(18)F]UCB-H: First-in-Human Study.
    Bretin F; Bahri MA; Bernard C; Warnock G; Aerts J; Mestdagh N; Buchanan T; Otoul C; Koestler F; Mievis F; Giacomelli F; Degueldre C; Hustinx R; Luxen A; Seret A; Plenevaux A; Salmon E
    Mol Imaging Biol; 2015 Aug; 17(4):557-64. PubMed ID: 25595813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics and 28-day test-retest repeatability and reproducibility of [
    Tuncel H; Boellaard R; Coomans EM; de Vries EF; Glaudemans AW; Feltes PK; García DV; Verfaillie SC; Wolters EE; Sweeney SP; Ryan JM; Ivarsson M; Lynch BA; Schober P; Scheltens P; Schuit RC; Windhorst AD; De Deyn PP; van Berckel BN; Golla SS
    J Cereb Blood Flow Metab; 2021 Jun; 41(6):1338-1350. PubMed ID: 34013797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of test-retest reproducibility of [
    Li S; Naganawa M; Pracitto R; Najafzadeh S; Holden D; Henry S; Matuskey D; Emery PR; Cai Z; Ropchan J; Nabulsi N; Carson RE; Huang Y
    Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1327-1338. PubMed ID: 33416954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic evaluation and test-retest reproducibility of [
    Finnema SJ; Nabulsi NB; Mercier J; Lin SF; Chen MK; Matuskey D; Gallezot JD; Henry S; Hannestad J; Huang Y; Carson RE
    J Cereb Blood Flow Metab; 2018 Nov; 38(11):2041-2052. PubMed ID: 28792356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: synthesis and preclinical characterization of [
    Zheng C; Holden D; Zheng MQ; Pracitto R; Wilcox KC; Lindemann M; Felchner Z; Zhang L; Tong J; Fowles K; Finnema SJ; Nabulsi N; Carson RE; Huang Y; Cai Z
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1482-1496. PubMed ID: 34761284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic Characterization of [
    Becker G; Warnier C; Serrano ME; Bahri MA; Mercier J; Lemaire C; Salmon E; Luxen A; Plenevaux A
    Mol Pharm; 2017 Aug; 14(8):2719-2725. PubMed ID: 28651055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical In Vitro and In Vivo Characterization of Synaptic Vesicle 2A-Targeting Compounds Amenable to F-18 Labeling as Potential PET Radioligands for Imaging of Synapse Integrity.
    Patel S; Knight A; Krause S; Teceno T; Tresse C; Li S; Cai Z; Gouasmat A; Carroll VM; Barret O; Gottmukkala V; Zhang W; Xiang X; Morley T; Huang Y; Passchier J
    Mol Imaging Biol; 2020 Aug; 22(4):832-841. PubMed ID: 31728839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics of [
    Goutal S; Guillermier M; Becker G; Gaudin M; Bramoullé Y; Luxen A; Lemaire C; Plenevaux A; Salmon E; Hantraye P; Barret O; Van Camp N
    EJNMMI Res; 2021 Apr; 11(1):36. PubMed ID: 33826008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.